Article

Functional impact of PCSK9 variants on LDL uptake in a knockout hepatic model

2026-03-17

Abstract excerpt

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a central regulator of low-density lipoprotein (LDL) cholesterol metabolism, yet the functional consequences of many clinically observed PCSK9 variants remain unknown. To establish a rigorous system for quantitative variant assessment, we generated a PCSK9 knockout (KO) HepG2 cell line through CRISPR/Cas9-mediated deletion of exons 2–8, effectively removing...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1048c268-5eef-58b7-a094-c6090a071a9c
DOI: 10.64898/2026.03.13.711724

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Functional impact of PCSK9 variants on LDL uptake in a knockout hepatic modelDOI 10.64898/2026.03.13.711724Read

New Loss-of-Function Mutations in PCSK9 Reduce Plasma LDL Cholesterol.Semantic proximity Read

[PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].Semantic proximity Read

PCSK9: a key modulator of cardiovascular health.Semantic proximity Read

Is It Ever Wise to Edit Wild-Type Alleles? Engineered CRISPR Alleles Versus Millions of Years of Human Evolution.Semantic proximity Read

PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes.Semantic proximity Read

Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition.Semantic proximity Read

A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants.Semantic proximity Read

Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants.Semantic proximity Read

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.Semantic proximity Read

Targeting PCSK9 for the treatment of hypercholesterolemia.Semantic proximity Read

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.Semantic proximity Read

Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture.Semantic proximity Read